M. Lacy

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

T. Therneau, R. Kyle, M. Gertz, 1997, The New England journal of medicine.

Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis.

G. Ahmann, R. Fonseca, A. Dispenzieri, 2001, Blood.

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

A. Dispenzieri, S. Rajkumar, S Kumar, 2013, Blood Cancer Journal.

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

D. Dingli, A. Dispenzieri, R. Kyle, 2016, Leukemia.

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen

S. Rajkumar, N. Callander, A. Stewart, 2016, Blood Cancer Journal.

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

R. Fonseca, S. Vincent Rajkumar, D. Dingli, 2012, British journal of haematology.

Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide.

R. Fonseca, A. Dispenzieri, V. Roy, 2011, Journal of Clinical Oncology.

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

S. Rajkumar, S Kumar, D. Dingli, 2023, Blood cancer journal.